Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07181837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Study acronym: ASCEND-AS
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Active, Not Recruiting → Recruiting Site details revised at 3 of 3 sitesv13 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  2. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 3 of 3 sitesv12 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  3. Site contacts updated at 1 of 3 sitesv11
  4. Study sites: 2 to 3v10
  5. Study sites: 3 to 2v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 2 to 3v8
  2. Site contacts updated at 1 of 2 sitesv7
  3. Start date changed from estimate of Oct 2025 to Oct 29, 2025v6
  4. Site contacts updated at 1 of 2 sitesv5
  5. Study sites: 1 to 2v4
  6. Trial status: Not Yet Recruiting to Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  7. Study sites: 0 to 1v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
Trial Details
NCT Number NCT07181837
Lead Sponsor MavriX Bio, LLC
Conditions Angelman Syndrome
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov